Jubilant Pharmova Ltd (BSE: 530019) is a Noida, Uttar Pradesh-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹15,556 Cr, it ranks #451 by market cap among the 6,197 Indian listed companies on FinBizNet, and #7 of 11 in Pharmaceutical CDMO and CRO Services. At ₹964.65 (as of 16 Nov 2026), the share price is 17.0% below its 52-week high of ₹1,162.00 and 22.7% above its 52-week low of ₹786.05. The share price is down 14.5% over one year and up 8.3% over three months.
| Current Price | ₹964.65 |
|---|---|
| Market Cap | ₹15,556 Cr |
| BSE Code | 530019 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | 39.1 |
| Return on Equity | 5.96% |
| Return on Assets | 3.62% |
| 52-Week Range | ₹786.05 – ₹1,162.00 |
| 1-Year Price Change | -14.5% |
| 3-Month Price Change | +8.3% |
| Beta (1Y) | 0.29 |
| Dividend Yield | 0.51% |
| Headquarters | Noida, Uttar Pradesh |
| Website | www.jubilantpharmova.com |
| Revenue | ₹2,370 Cr |
|---|---|
| Net Profit | ₹31 Cr |
| Net Margin | 1.3% |
| EPS (Basic) | ₹1.97 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Jubilant Pharmova Ltd reported revenue of ₹2,370 Cr in Q2 FY27, up 20.5% from ₹1,966 Cr in Q2 FY26 and up 6.3% from ₹2,229 Cr in Q1 FY27. It posted a net profit of ₹31 Cr for the quarter, against a net profit of ₹120 Cr in Q2 FY26 (down 74.1%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1,901 Cr (Q1 FY26) to ₹2,370 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹2,370 Cr | ₹31 Cr | 1.3% |
| Q1 FY27 | ₹2,229 Cr | ₹56 Cr | 2.5% |
| Q4 FY26 | ₹2,290 Cr | ₹119 Cr | 5.2% |
| Q3 FY26 | ₹2,123 Cr | ₹56 Cr | 2.6% |
| Q2 FY26 | ₹1,966 Cr | ₹120 Cr | 6.1% |
| Q1 FY26 | ₹1,901 Cr | ₹103 Cr | 5.4% |
| Q4 FY25 | ₹1,929 Cr | ₹151 Cr | 7.8% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 47.68% of Jubilant Pharmova Ltd's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 43.9% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distr
1. Pharmaceuticals (Excluding Drug Discovery and Development Solutions)-This segment offers specialty pharmaceuticals, including radiopharmaceuticals and allergy therapy products; contract development and manufacturing services; generics, such as solid dosage formulations; and India branded pharmaceuticals. 2. Contract Research and Development Services (Excl. Proprietary Novel Drugs)-This segment offers drug discovery and development services, as well as clinical data software and service solutions. 3. Proprietary Novel Drugs-This segment offers biopharmaceutical products to address oncology and autoimmune diseases. 4. Inter-Segment Revenue-0
1. Radio Pharma-44.6% 2. Allergy Immunotherapy-9.6% 3. Contract Development and Manufacturing Organization - Sterile Injectables-21.9% 4. Contract Research, Development and Manufacturing Organization-15.3% 5. Generics-9.3% 7. Unallocable Corporate-0.7%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Divis Laboratories Limited | ₹3,01,758 Cr | 118.4 | 16.19% | ₹3,676 Cr | +71.9% |
| Anthem Biosciences Limited | ₹53,926 Cr | 90.1 | 19.45% | ₹594 Cr | +34.5% |
| Sai Life Sciences Limited | ₹40,755 Cr | 116.1 | 15.13% | ₹659 Cr | +120.3% |
| Onesource Specialty Pharma Limited | ₹18,138 Cr | n/m | -1.26% | ₹516 Cr | -9.4% |
| Cohance Lifesciences Ltd | ₹17,756 Cr | 100.6 | 5.11% | ₹477 Cr | -35.2% |
| Syngene International Ltd. | ₹17,630 Cr | 56.9 | 6.62% | ₹833 Cr | -27.9% |
| Jubilant Pharmova Ltd | ₹15,556 Cr | 39.1 | 5.96% | ₹2,370 Cr | -14.5% |
| Concord Biotech Ltd | ₹12,495 Cr | 24.2 | 13.54% | ₹309 Cr | -14.8% |
| Blue Jet Healthcare Ltd | ₹10,140 Cr | 38 | 19.88% | ₹376 Cr | -9.8% |
Listed by market capitalisation. Ratios are shown for context only.
Jubilant Pharmova Ltd is trading at ₹964.65, with a market capitalisation of ₹15,556 Cr.
Jubilant Pharmova Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Jubilant Pharmova Ltd has a P/E of 39.1 and a return on equity of 5.96%.
Jubilant Pharmova Ltd is listed on the BSE under the scrip code 530019.
Jubilant Pharmova Ltd's share price is down 14.5% over one year and up 8.3% over three months. Its 52-week range is ₹786.05 to ₹1,162.00.
In Q2 FY27, Jubilant Pharmova Ltd reported revenue of ₹2,370 Cr and net profit of ₹31 Cr, with basic EPS of ₹1.97 (consolidated, parsed from the company's exchange filing).
Jubilant Pharmova Ltd reported revenue of ₹2,370 Cr in Q2 FY27, up 20.5% from ₹1,966 Cr in Q2 FY26 and up 6.3% from ₹2,229 Cr in Q1 FY27.
Promoters held 47.68% of Jubilant Pharmova Ltd's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.